1
Michael L Edwards, Paul J Cox, Shelley Amendola, Stephanie D Deprets, Timothy A Gillespy, Christopher D Edlin, Andrew D Morley, Charles J Gardner, Brian Pedgrift, Herve Bouchard, Didier Babin, Laurence Gauzy, Alain Le Brun, Tahir N Majid, John C Reader, Lloyd J Payne, Nawaz M Khan, Michael Cherry: Benzimidazoles. Aventis Pharmaceuticals, Paul Darkes, George Wang, Raymond S Parker III, May 24, 2005: US06897208 (67 worldwide citation)

The invention is directed to physiologically active compounds of the general formula (Ix) and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula ...


2
Paul J Cox, Tahir N Majid, Justine Yeun Quai Lai, Andrew D Morley, Shelley Amendola, Stephanie D Deprets, Christopher Edlin, Charles J Gardner, Dorothea Kominos, Brian L Pedgrift, Frank Halley, Timothy A Gillespy, Michael Edwards, Francois F Clerc, Conception Nemecek, Olivier Houille, Dominique Damour, Herve Bouchard, Daniel N A Bezard, Chantal Carrez: Azaindoles. Aventis Pharmaceuticals, Paul Darkes, George Wang, Raymond Parker, May 24, 2005: US06897207 (63 worldwide citation)

The invention is directed to physiologically active compounds of general formula (I): and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I) ...


3
Paul J Cox, Tahir N Majid, Justine Y Q Lai, Andrew D Morley, Shelley Amendola, Stephanie D Deprets, Christopher Edlin: Azaindoles. Aventis Pharma, George G Wang, August 3, 2004: US06770643 (36 worldwide citation)

The invention is directed to compositions containing physiologically active compounds of general formula (I):


4
Michael L Edwards, Paul J Cox, Shelley Amendola, Stephanie D Deprets, Timothy A Gillespy, Christopher D Edlin, Andrew D Morley, Charles J Gardner, Brian Pedgrift, Herve Bouchard, Didier Babin, Laurence Gauzy, Alain Le Brun, Tahir N Majid, John C Reader, Lloyd J Payne, Nawaz M Khan, Michael Cherry: Benzimidazoles. Aventis Pharmaceuticals, Brian R Morrill, October 16, 2012: US08288425 (32 worldwide citation)

The invention is directed to physiologically active compounds of the general formula (Ix) and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula ...


5
Paul J Cox, Tahir N Majid, Justine Yeun Quai Lai, Andrew D Morley, Shelley Amendola, Stephanie D Deprets, Christopher Edlin, Charles J Gardner, Dorothea Kominos, Brian L Pedgrift, Frank Halley, Timothy A Gillespy, Michael Edwards, Francois F Clerc, Conception Nemecek, Olivier Houille, Dominique Damour, Herve Bouchard, Daniel N A Bezard, Chantal Carrez: Azaindoles for inhibiting aurora2 and other kinases. Aventis Pharmaceuticals, Jiang Lin, May 17, 2011: US07943616 (1 worldwide citation)

The invention is directed to physiologically active compounds of general formula (I):— and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I ...


6
Paul J Cox, Tahir N Majid, Shelley Amendola, Stephanie D Deprets, Christoper Edlin, Justine Y Q Lai, Andrew D Morley: Azaindoles. Aventis Pharma, Ross J Oehler, Aventis Pharmaceuticals, October 7, 2004: US20040198737-A1

Chemical compositions containing physiologically active compounds of general formula (I): 1 wherein R1 is aryl or heteroaryl; R2 represents hydrogen, acyl, cyano, halo, lower alkenyl or lower alkyl optionally substituted by a substituent selected from cyano, heteroaryl, heterocycloalkyl, -Z1R8, —C(O ...


7
Michael L Edwards, Paul J Cox, Shelley Amendola, Stephanie D Deprets, Timothy A Gillespy, Christopher D Edlin, Andrew D Morley, Charles J Gardner, Brian Pedgrift, Herve Bouchard, Didier Babin, Laurence Gauzy, Alain Le Brun, Tahir N Majid, John C Reader, Lloyd J Payne, Nawaz M Khan, Michael Cherry: Benzimidazoles. Ross J Oehler, Aventis Pharmaceuticals, March 11, 2004: US20040048868-A1

The invention is directed to physiologically active compounds of the general formula (Ix) 1 and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formu ...


8
Paul J Cox, Tahir N Majid, Justine Yeun Quai Lai, Andrew D Morley, Shelley Amendola, Stephanie D Deprets, Christopher Edlin, Charles J Gardner, Dorothea Kominos, Brian L Pedgrift, Frank Halley, Timothy A Gillespy, Michael Edwards, Francois F Clerc, Conception Nemecek, Olivier Houille, Dominique Damour, Herve Bouchard, Daniel NA Bezard, Chantal Carrez: Azaindoles. Ross J Oehler, Aventis Pharmaceuticals, March 18, 2004: US20040053931-A1

The invention is directed to physiologically active compounds of general formula (I):— 1 and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula ...


9
Paul J Cox, Tahir N Majid, Justine YQ Lai, Andrew D Morley, Shelley Amendola, Stephanie D Deprets, Christopher Edlin: Azaindoles. Ross J Oehler, Aventis Pharmaceuticals, January 15, 2004: US20040009983-A1

The invention is directed to compositions containing physiologically active compounds of general formula (I): 1 wherein R1 is aryl or heteroaryl; R2 represents hydrogen, acyl, cyano, halo, lower alkenyl or lower alkyl optionally substituted by a substituent selected from cyano, heteroaryl, heterocyc ...


10
Garry Fenton, Tahir N Majid, Malcolm N Palfreyman: Compounds as PDE IV and TNF-inhibitors. Ross J Oehler, Aventis Pharmaceuticals, January 16, 2003: US20030013713-A1

This invention is directed to a [di(ether or thioether)heteroaryl or fluoro substituted aryl] compound or an N-oxide thereof or a pharmaceutically acceptable salt thereof, which is useful for inhibiting the production or physiological effects of TNF in the treatment of a patient suffering from a dis ...